28
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Oxidative Stress in Ischemic Heart Disease

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          One of the novel interesting topics in the study of cardiovascular disease is the role of the oxidation system, since inflammation and oxidative stress are known to lead to cardiovascular diseases, their progression and complications. During decades of research, many complex interactions between agents of oxidative stress, oxidation, and antioxidant systems have been elucidated, and numerous important pathophysiological links to na number of disorders and diseases have been established. This review article will present the most relevant knowledge linking oxidative stress to vascular dysfunction and disease. The review will focus on the role of oxidative stress in endotheleial dysfunction, atherosclerosis, and other pathogenetic processes and mechanisms that contribute to the development of ischemic heart disease.

          Related collections

          Most cited references357

          • Record: found
          • Abstract: not found
          • Article: not found

          2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

              We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
                Bookmark

                Author and article information

                Contributors
                Journal
                Oxid Med Cell Longev
                Oxid Med Cell Longev
                OMCL
                Oxidative Medicine and Cellular Longevity
                Hindawi
                1942-0900
                1942-0994
                2020
                28 December 2020
                : 2020
                : 6627144
                Affiliations
                1Department for Heart and Vascular Diseases, Osijek University Hospital, Osijek, Croatia
                2Department of Physiology and Immunology, Faculty of Medicine, University J.J. Strossmayer in Osijek, Osijek, Croatia
                3Department of Rheumatology and Clinical Immunology, Osijek University Hospital, Osijek, Croatia
                4Faculty of Medicine, University J.J. Strossmayer in Osijek, Osijek, Croatia
                5Department for Emergency Medical Services of the Osijek-Baranja county, Osijek, Croatia
                6Department of Internal Medicine, Faculty of Medicine, University J.J. Strossmayer in Osijek, Osijek, Croatia
                Author notes

                Academic Editor: Andreas Daiber

                Author information
                https://orcid.org/0000-0001-7843-1079
                https://orcid.org/0000-0001-6687-8500
                https://orcid.org/0000-0001-6903-2439
                https://orcid.org/0000-0002-0975-3039
                https://orcid.org/0000-0002-9890-6489
                Article
                10.1155/2020/6627144
                7785350
                33456670
                6716273e-967c-4e81-8493-7f66abf027ba
                Copyright © 2020 Aleksandar Kibel et al.

                This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 19 November 2020
                : 27 November 2020
                : 7 December 2020
                Categories
                Review Article

                Molecular medicine
                Molecular medicine

                Comments

                Comment on this article